MedTrace Logo

A Study of Combination Therapies to Treat COVID-19 Infection

NCT04459702 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-04-08

No results posted yet for this study

Summary

This study seeks to determine whether dual or quadruple therapy is more effective in treating COVID-19.

Conditions

  • COVID
  • COVID-19
  • Corona Virus Infection
  • Coronavirus Infection
  • Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere
  • Coronavirus-19
  • SARS-CoV 2
  • SARS Pneumonia

Interventions

DRUG

hydroxychloroquine

Treatment with the drug hydroxychloroquine

DRUG

Azithromycin

Treatment with the drug azithromycin

DRUG

Ritonavir

Treatment with the drug ritonavir

DRUG

Lopinavir

Treatment with the drug lopinavir

Sponsors & Collaborators

  • Big Corona Ltd.

    collaborator UNKNOWN

  • ProgenaBiome

    lead OTHER

Principal Investigators

  • Sabine Hazan, MD · ProgenaBiome

  • Thomas Borody, MD, PhD, · Big Corona Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-31
Primary Completion
2021-07-31
Completion
2021-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04459702 on ClinicalTrials.gov